Is Telix Pharmaceuticals Set for Another Big Year After Its 56% Revenue Jump?
Source: Kapitales Research
Highlights:
Telix Pharmaceuticals Limited (ASX: TLX) delivered FY2025 revenue of US$804 million, marking a 56% year-on-year increase at the time of writing.
Precision Medicine revenue climbed 22% to US$622 million at the time of writing, supported by strong imaging product demand.
The company expects FY2026 revenue between US$950 million and US$970 million at the time of writing, with R&D guidance of US$200 million to US$240 million at the time of writing.
Telix Pharmaceuticals Limited (ASX: TLX) shares were trading near AU$10.310, rising nearly 13% at the time of writing after the company released its FY2025 results. The radiopharmaceutical developer posted record revenue and outlined a clear plan to reinvest earnings into expanding both its commercial footprint and late-stage therapeutic pipeline.
What powered the FY2025 growth?
The company reported total revenue of US$804 million for FY2025, reflecting a 56% increase compared to the previous year at the time of writing. A major contributor was its Precision Medicine division, which generated US$622 million in revenue, up 22% at the time of writing. Telix also reported adjusted EBITDA of US$40 million at the time of writing, indicating that profitability remained intact despite significant spending on expansion and research initiatives.
How strong is the pipeline outlook?
Beyond commercial success, Telix is advancing several clinical programs across prostate, kidney, brain and bone cancer indications. Management indicated that research and development spending will remain a strategic priority, with FY2026 R&D guidance set between US$200 million and US$240 million at the time of writing.
What’s next for FY2026?
Looking ahead, the company has projected FY2026 revenue in the range of US$950 million to US$970 million at the time of writing. The forecast is based on currently approved products and geographic expansion, with potential upside tied to regulatory milestones and new product launches.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Is Telix Pharmaceuticals Set for Another Big Year After Its 56% Revenue Jump?
Highlights:
Telix Pharmaceuticals Limited (ASX: TLX) shares were trading near AU$10.310, rising nearly 13% at the time of writing after the company released its FY2025 results. The radiopharmaceutical developer posted record revenue and outlined a clear plan to reinvest earnings into expanding both its commercial footprint and late-stage therapeutic pipeline.
What powered the FY2025 growth?
The company reported total revenue of US$804 million for FY2025, reflecting a 56% increase compared to the previous year at the time of writing. A major contributor was its Precision Medicine division, which generated US$622 million in revenue, up 22% at the time of writing. Telix also reported adjusted EBITDA of US$40 million at the time of writing, indicating that profitability remained intact despite significant spending on expansion and research initiatives.
How strong is the pipeline outlook?
Beyond commercial success, Telix is advancing several clinical programs across prostate, kidney, brain and bone cancer indications. Management indicated that research and development spending will remain a strategic priority, with FY2026 R&D guidance set between US$200 million and US$240 million at the time of writing.
What’s next for FY2026?
Looking ahead, the company has projected FY2026 revenue in the range of US$950 million to US$970 million at the time of writing. The forecast is based on currently approved products and geographic expansion, with potential upside tied to regulatory milestones and new product launches.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au